FDA Law Blog

SEPTEMBER 19, 2023

The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. But it is not always clear which types of patents are eligible for listing in the Orange Book. The FDA Commissioner is quoted as saying that “[t]he FDA stands ready to assist the FTC.

Drugs 105

Drugs Branding Drug Delivery Systems Generic Drugs 105

The Pharma Data

JANUARY 17, 2021

The Company will continue to leverage its scientific expertise and operations in Europe and North America for product development and optimization while it plans to add significant commercial experience in the fields of manufacturing, distribution, marketing and sales. Drug Formulations and Delivery. XPhyto Therapeutics Corp.

Production 40

Production Drug Delivery Development Drugs 40

The Pharma Data

JANUARY 27, 2021

The addition of in-house, scalable commercial drug manufacturing capability is expected to add significant value and optionality to XPhyto’s drug formulation business. In 2020, XPhyto reported significant advancements in four drug formulation development programs. About XPhyto Therapeutics Corp.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

XTalks

AUGUST 30, 2022

Due to consistent changes in pharmaceutical regulation, pandemic-related disturbances and the ongoing effects of digitization, visionary leaders could find themselves co-constructing their vision. Strategic leaders know how to think critically and navigate through daily challenges that are bound to emerge in this competitive market.

Life Science 105

Life Science Generic Drugs Drug Delivery Compliance 105